Andrew Stewart, MD
- DIRECTOR, DIABETES OBESITY AND METABOLISM INSTITUTE
- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
Research Topics:
Autoimmunity, Cell Biology, Cell Cycle, Cell Division, Cellular Differentiation, DNA Replication, Diabetes, Gene Discovery, Gene Expressions, Gene Therapy, Genomics, Growth Factors and Receptors, Hormones, Immunosuppression, Insulin, Knockout Mice, Obesity, Oncogenes, Phosphorylation, Protein Kinases, Proteomics, Receptors, Transgenic Mice, Transplantation, Tumor Suppressor Genes
Dr. Andrew Stewart’s research focuseson understanding and developing novel means for inducing the replication and regeneration of insulin-producing pancreatic beta cells. As Chief of the Division of Endocrinology and Metabolism at the University of Pittsburgh School of Medicine, Dr. Stewart and his research team were the first to demonstrate that adult human beta cells could be induced to replicate at substantial rates. Three long-time colleagues from that group are joining him: Donald K. Scott, PhD; Adolfo García-Ocaña, PhD; and Rupangi Chhaya Vasavada, PhD, as Professors in the Division of Endocrinology, Diabetes and Bone Disease, and as members of the Institute. Dr. Stewart, who has also been named Professor of Medicine (Endocrinology, Diabetes & Bone Diseases) will oversee the continued expansion of the Institute through the recruitment of additional researchers.
Dr. Stewart has devoted more than 30 years to patient care and scientific research, and received numerous honors, including the prestigious Aurbach award of The Endocrine Society, and also served as Program Chair for the American Diabetes Association Annual Scientific Sessions in 2010 and 2012. He has published more than 230 clinical and scientific papers in journals including the Proceedings of the National Academy of Sciences, The New England Journal of Medicine, and Science. He received his bachelor's degree from Trinity College in Hartford, Connecticut, and his MD from Columbia University, College of Physicians and Surgeons, in New York. He served as a fellow in Endocrinology and Metabolism and faculty member at Yale University School of Medicine in Connecticut, and later as Chief of the Division of Endocrinology at the University of Pittsburgh. Dr. Stewart currently has strong funding support from the National Institutes of Health, the Juvenile Diabetes Research Foundation, and other agencies.
Read about Dr. Stewart's research on the Inside Mount Sinai blog.
Multi-Disciplinary Training Areas
Development, Regeneration, and Stem Cells [DRS], Genetics and Data Science [GDS], Pharmacology and Therapeutics Discovery [PTD]Education
MD, Columbia University, College of Physicians and Surgeons
Dr. Andrew Stewart is the Scientific Director of the Diabetes, Obesity and Metabolism Institute (DOMI). He an authority on human insulin-producing pancreatic beta cell replication and regeneration for people with diabetes. His research focuses on understanding and developing novel therapies for inducing human beta cell regeneration, from gene therapy to small molecule drug discovery. His group was the first to demonstrate that growth factors could drive beta cell replication in vivo in mammals, and also improve glucose control in living animals. His group was also the first to carefully define cell cycle control in the rodent and human beta cell. They were also the first to report that small molecule drugs that inhibit the enzyme DYRK1A are able to induce human beta cells to replicate, and to reverse diabetes in vivo in mice transplanted with human beta cells. He is actively involved in developing next-generation DYRK1A inhibitors for human diabetes, and understanding why human beta cells are so refractory to replication. His work has been continually supported by the NIH/NIDDK and the JDRF.
Please visit the Stewart Laboratory.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Stewart did not report having any of the following types of financial relationships with industry during 2019 and/or 2020: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.